Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Specimen Handling 113Magnetic Resonance Spectroscopy 113Cyclophosphamide 106pembrolizumab 82Radiotherapy 79Nivolumab 68Cisplatin 67fludarabine 64Carboplatin 59Biopsy 54Standard of Care 46Radiosurgery 43Gemcitabine 43Paclitaxel 42Dexamethasone 41Rituximab 37Radiation 37Doxorubicin 37Blood Specimen Collection 37Cytarabine 36Bevacizumab 35venetoclax 34fludarabine phosphate 33Surveys and Questionnaires 32Temozolomide 31Radiotherapy, Intensity-Modulated 31Capecitabine 31Practice Guidelines as Topic 28Etoposide 28Oxaliplatin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × loncastuximab tesirine × 30 days × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT05464719 2026-05-20

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma

NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05672251 2026-05-11

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡